Study on Tiragolumab and Atezolizumab Combination vs. Placebo and Atezolizumab for Untreated Advanced Non-Small Cell Lung Cancer

Inclusion Criteria

• Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have a confirmed diagnosis of locally advanced or recurrent non-small cell lung cancer (NSCLC) that cannot be removed by surgery or treated with radiation, or have Stage IV NSCLC that has spread.
• Have not received any prior treatment for metastatic NSCLC.
• Have high levels of PD-L1 protein in the tumor tissue.
• Have measurable cancer according to standard criteria.
• Have adequate blood cell counts and organ function.
• For participants in the extended China enrollment phase: must be a current resident of mainland China or Taiwan and of Chinese ancestry.

Exclusion Criteria

• Have known genetic mutations in the EGFR gene or ALK fusion oncogene.
• Have untreated or worsening cancer that has spread to the brain or spinal cord.
• Have a history of autoimmune diseases or immune system deficiencies.
• Have a history of certain lung diseases like idiopathic pulmonary fibrosis or active lung inflammation.
• Have had other cancers within the past 5 years, except for certain non-threatening cancers.
• Have had a severe infection within 4 weeks before starting the study treatment.
• Test positive for HIV.
• Have active hepatitis B or C infections.
• Have received any investigational therapy within 28 days before starting the study treatment.
• Have previously been treated with certain immune therapies, including CD137 agonists or immune checkpoint inhibitors.
• Have used systemic immune-stimulating agents within 4 weeks or 5 drug elimination half-lives before starting the study treatment.